Afamelanotide (Scenesse)

1. Overview

Afamelanotide (trade name Scenesse; also known as CUV1647, NDP-MSH, NDP-alpha-MSH, [Nle4, D-Phe7]-alpha-MSH, and Melanotan I) is a synthetic 13-amino-acid peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It has a molecular formula of C78H111N21O19 and a molecular weight of 1646.85 g/mol [5][12]. Its amino acid sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, differing from native alpha-MSH by two key substitutions: norleucine replaces methionine at position 4, and D-phenylalanine replaces L-phenylalanine at position 7. These modifications confer approximately 100-fold greater potency than native alpha-MSH, significantly increased enzymatic stability, and prolonged biological activity [5][11].

Afamelanotide is a first-in-class melanocortin-1 receptor (MC1R) agonist. It was originally developed by researchers at the University of Arizona and later brought to clinical development by Clinuvel Pharmaceuticals (formerly Epitan), an Australian biopharmaceutical company. It is the first melanocortin receptor agonist to receive regulatory approval as a systemic therapeutic agent. The European Medicines Agency (EMA) granted conditional marketing authorization under exceptional circumstances in December 2014, and the U.S. Food and Drug Administration (FDA) approved it on October 8, 2019, both for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) [1][12][13].

Afamelanotide is formulated as a biodegradable subcutaneous implant containing 16 mg of the peptide in a poly(DL-lactide-co-glycolide) matrix. It is administered by a healthcare professional into the subcutaneous tissue above the anterior supra-iliac crest. The implant provides controlled release over approximately 5-10 days, with most of the dose released within the first 48 hours [5][12].

Molecular Formula

C78H111N21O19

Molecular Weight

1646.85 g/mol

Sequence

Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

Half-life

~15 hours (subcutaneous implant); ~30 minutes (other routes)

Formulation

16 mg biodegradable subcutaneous implant (poly-DL-lactide-co-glycolide)

FDA Status

Approved (October 8, 2019) for EPP in adults

EMA Status

Approved (December 22, 2014) for EPP in adults

Manufacturer

Clinuvel Pharmaceuticals (ASX: CUV)

CAS Number

75921-69-6

DrugBank ID

DB04931

2. Mechanism of Action

Afamelanotide exerts its effects primarily through binding to the melanocortin-1 receptor (MC1R) on epidermal melanocytes, though it has affinity for other melanocortin receptor subtypes (MC3R, MC4R, MC5R) as well [5][8]. The conserved pharmacophore His-Phe-Arg-Trp is critical for receptor interaction, and the D-Phe7 substitution enhances binding affinity and receptor residence time [20].

Melanogenesis and Eumelanin Production

MC1R activation by afamelanotide triggers the cAMP-PKA signaling cascade, leading to phosphorylation of CREB (cAMP response element-binding protein) and upregulation of MITF (microphthalmia-associated transcription factor). MITF in turn drives transcription of key melanogenic enzymes -- tyrosinase, TRP-1, and TRP-2 -- resulting in increased synthesis of eumelanin, the brown-black photoprotective pigment. Critically, afamelanotide preferentially stimulates eumelanin over pheomelanin production, which is clinically important because eumelanin is photoprotective while pheomelanin can generate reactive oxygen species upon UV exposure [5][7][11].

Studies in human volunteers demonstrated that afamelanotide induces visible skin darkening (increased melanin density) even without UV exposure, and that the effect is particularly pronounced in individuals carrying MC1R variant alleles -- the population most deficient in baseline eumelanin and most in need of photoprotection [11].

DNA Repair Enhancement

Beyond melanogenesis, MC1R signaling activated by afamelanotide enhances nucleotide excision repair (NER) of UV-induced DNA photoproducts, including cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts. This effect operates independently of pigmentation and involves cAMP-mediated upregulation of DNA repair enzymes. This DNA repair function was confirmed in vivo in xeroderma pigmentosum patients, where afamelanotide reduced UV-induced DNA photodamage [17].

Antioxidant and Anti-inflammatory Activity

Afamelanotide-mediated MC1R activation induces antioxidant defenses including upregulation of heme oxygenase-1 (HO-1) and superoxide dismutase, and activates the PI3K/Akt/Nrf2 signaling pathway to protect against oxidative stress. Additionally, MC1R signaling modulates NF-kB-mediated inflammatory pathways, reducing production of pro-inflammatory cytokines. These combined anti-inflammatory and antioxidant properties underlie the rationale for investigating afamelanotide in stroke neuroprotection [10].

Neuroprotective Mechanisms

In the context of acute ischemic stroke, afamelanotide's MC1R agonism has been shown in preclinical models to ameliorate neuroinflammation, reduce blood-brain barrier disruption via the CREB/Nr4a1/NF-kB pathway, and attenuate oxidative neuronal apoptosis through the PI3K/Akt/Nrf2 pathway. These effects provided the rationale for the CUV801 clinical trial [10].

3. Researched Applications

Erythropoietic Protoporphyria (EPP) -- Approved Indication

Evidence level: Strong (Phase III RCTs, long-term observational data, regulatory approval)

EPP is a rare inherited disorder of heme biosynthesis in which accumulation of free protoporphyrin IX in erythrocytes, plasma, and skin causes severe phototoxicity upon exposure to visible light (particularly in the 400-410 nm Soret band range). Patients experience excruciating burning pain, erythema, and edema within minutes of sunlight exposure, dramatically limiting their ability to participate in outdoor activities.

Afamelanotide addresses EPP phototoxicity through multiple complementary mechanisms: increased eumelanin acts as a broad-spectrum photoprotective filter absorbing visible and UV light, enhanced DNA repair addresses photodamage, and antioxidant/anti-inflammatory activity mitigates the downstream effects of protoporphyrin-mediated phototoxicity [1][2][6][16].

Two pivotal Phase III randomized controlled trials demonstrated statistically significant improvements. The CUV039 US trial (93 patients) showed median pain-free time in direct sunlight of 69.4 hours with afamelanotide versus 40.8 hours with placebo (P=0.04) over 6 months [1]. The CUV029 EU trial (74 patients) demonstrated 6.0 vs 0.8 hours of pain-free time (P=0.005) and fewer phototoxic reactions (77 vs 146, P=0.04) over 9 months [1]. Long-term observational data in 115 patients over up to 8 years confirmed sustained quality-of-life improvement from 31% to 74% of maximum score, with no significant long-term adverse effects [2]. Real-world observational studies in Germany and the US have continued to confirm the favorable benefit-risk profile [9][14][15].

Additionally, afamelanotide has shown a dose-dependent protective effect against protoporphyrin-induced liver damage, a serious complication of EPP that can progress to liver failure [18].

Vitiligo

Evidence level: Moderate (Phase II RCT; Phase III ongoing)

Vitiligo is an autoimmune condition causing progressive depigmentation of the skin. A randomized multicenter Phase II trial demonstrated that afamelanotide combined with narrowband UV-B (NB-UVB) phototherapy produced significantly superior and faster repigmentation compared to NB-UVB alone. At day 168, repigmentation was 48.64% in the combination group versus 33.26% with NB-UVB monotherapy. Onset of repigmentation was earlier: 41 vs 61 days on the face and 46 vs 69 days on upper extremities [3].

Clinuvel's Phase III pivotal trial CUV105 completed enrollment of over 200 patients across three continents in 2025. The primary endpoint is T-VASI50 (at least 50% total body surface area repigmentation as measured by the Total Vitiligo Area Scoring Index). Topline results are anticipated in the second half of 2026. If successful, this would represent a non-immunosuppressive systemic treatment option for vitiligo [3].

Xeroderma Pigmentosum (XP)

Evidence level: Preliminary (Phase II pilot, n=3)

Xeroderma pigmentosum is a rare genetic disorder characterized by defective DNA repair, leading to extreme UV sensitivity and high skin cancer risk. The CUV156 study treated three XP variant patients with afamelanotide and demonstrated reduced UV-induced DNA photodamage, confirming that afamelanotide's DNA repair enhancement is clinically relevant even in a population with inherent DNA repair deficiencies [17].

Acute Ischemic Stroke

Evidence level: Preliminary (Phase IIa proof-of-concept, n=6)

The CUV801 open-label Phase IIa trial tested afamelanotide in 6 acute ischemic stroke patients within 24 hours of symptom onset who were ineligible for revascularization therapies. Patients received up to 4 implants (Days 0, 1, 7, 8). The drug was well tolerated, and in surviving patients, the median NIHSS score improved from 6 to 2 by Day 7. Penumbral tissue showed radiological improvement (Tmax volume from 23 mL to 4 mL by Day 9). These preliminary results support further investigation in randomized trials [10].

Polymorphic Light Eruption (PLE)

Evidence level: Moderate (RCT data available)

Clinical trials have demonstrated afamelanotide's efficacy in preventing PLE, a common photosensitivity disorder. RCT evidence supports reduced severity and frequency of PLE episodes in afamelanotide-treated patients [7][8].

Solar Urticaria

Evidence level: Preliminary (small studies)

Limited clinical data suggest afamelanotide may reduce symptoms of solar urticaria, a rare condition characterized by hives upon sunlight exposure, through its photoprotective melanogenic effects [7][8].

Hailey-Hailey Disease

Evidence level: Preliminary (case series)

Small studies have reported improvement in Hailey-Hailey disease (familial benign chronic pemphigus), a genetic blistering skin condition, with afamelanotide treatment [7][8].

Acne Vulgaris

Evidence level: Preliminary (small case series)

In 3 patients with mild-to-moderate facial acne, a 16 mg afamelanotide implant led to decreased total and inflammatory acne lesion counts at 56 days post-administration [8].

Skin Cancer Prevention in Organ Transplant Recipients

Evidence level: Preliminary (Phase II trials initiated)

Phase II trials were initiated in 2007 in Australia and Europe to evaluate afamelanotide's ability to reduce actinic keratoses and squamous cell carcinomas in immunosuppressed organ transplant recipients. Approximately 200 patients were enrolled. The rationale is that afamelanotide-induced eumelanin provides photoprotection and DNA repair enhancement in a population with markedly elevated skin cancer risk [8].

Variegate Porphyria

Evidence level: Preliminary (trials planned/initiated)

Afamelanotide is being investigated for variegate porphyria, another photosensitive porphyria related to EPP. Clinical trials were outlined between 2022-2023 [17].

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published clinical research and the approved prescribing information. The only approved formulation is the 16 mg subcutaneous implant.

Pharmacokinetic Parameters

Following administration of a single 16 mg subcutaneous implant in 12 healthy adults [5]:

• Cmax: 3.7 +/- 1.3 ng/mL
• Tmax: 36 hours (median)
• AUC (0-inf): 138.9 +/- 42.6 hr*ng/mL
• Apparent half-life: ~15 hours (subcutaneous implant); ~30 minutes (other routes)
• Release profile: Most of dose released within first 48 hours; >90% by day 5; plasma levels undetectable by day 10
• Metabolism: May undergo hydrolysis; metabolic profile not fully characterized
• Bioavailability: High variability in plasma concentrations observed between subjects

6. Safety and Side Effects

Afamelanotide has a well-characterized safety profile based on Phase III clinical trials, long-term observational studies of up to 8 years, and post-marketing surveillance data [1][2][12][15].

Common Adverse Effects (>10%)

• Nausea and headache are classified as very common (affecting >10% of patients)

Common Adverse Effects (1-10%)

• Implant site reactions (discoloration, pain, erythema at insertion site)
• Back pain
• Upper respiratory tract infections, nasopharyngitis, oropharyngeal pain, cough
• Darkening of melanocytic nevi (moles)
• Decreased appetite
• Migraine and dizziness
• Fatigue, weakness, lethargy, somnolence
• Hot flashes and flushing
• Abdominal pain, diarrhea, vomiting
• Development of new freckles, spots, or warts
• Pruritus (itchy skin)

Hyperpigmentation

Transient skin darkening is an expected pharmacological effect, not a side effect per se. Approximately one-third of patients experience mild hyperpigmentation at the implant site. Some patients experience darkening of pre-existing moles. Hyperpigmentation of oral soft tissues has also been reported [12].

Long-term Safety

No late effects have been reported in volunteers followed for 25 years after first exposure or after continuous long-term application of up to 8 years in EPP patients. An immunogenic potential has been excluded. A large German cohort observational study (2025) confirmed that the real-world safety profile is consistent with clinical trial data [2][5][15].

Key Monitoring Requirements

• Full-body skin examination twice yearly is recommended to assess and monitor pigmented lesions and other skin abnormalities, particularly in patients with a personal history of skin cancer [12][13]
• Monitoring of pre-existing moles for changes in size, shape, or color
• Vitamin D levels should be monitored (vitamin D deficiency was identified as a frequent finding in long-term studies) [15]

Contraindications and Precautions

• Patients with severe hepatic impairment or severe renal impairment
• Patients with known hypersensitivity to afamelanotide or any excipient
• Caution in patients with a history of melanoma or other skin malignancies
• Not studied in pregnant or lactating women; reproductive safety data limited

Drug Interactions

No formal drug interaction studies have been published. Afamelanotide may undergo hydrolysis, but its metabolic profile has not been fully characterized [5][12].

7. Regulatory Status

European Medicines Agency (EMA)

Scenesse received conditional marketing authorization under exceptional circumstances on December 22, 2014, for the prevention of phototoxicity in adult patients with a confirmed diagnosis of erythropoietic protoporphyria. The "exceptional circumstances" designation reflects the inability to obtain complete efficacy data due to the extreme rarity of EPP. Scenesse was withdrawn from the Community Register of Orphan Medicinal Products in December 2024 at the end of its 10-year period of market exclusivity. In September 2025, the EMA approved a label amendment allowing year-round treatment (every 2 months without annual limit), removing the previous restriction of maximum 4 implants per year [13].

U.S. Food and Drug Administration (FDA)

Scenesse was approved by the FDA on October 8, 2019 (NDA 210797), to increase the amount of pain-free time spent in sunlight in adult patients with a confirmed diagnosis of EPP. It is available in the US under a restricted distribution program. Administration must be performed by a healthcare professional trained in the subcutaneous implant procedure [12].

Other Markets

Clinuvel has pursued regulatory pathways in additional markets. The drug is available through compassionate use and named-patient programs in countries where full regulatory approval has not yet been obtained.

Orphan Drug Designations

Afamelanotide has received orphan drug designations for EPP from both the FDA and EMA, reflecting the rarity of the condition (estimated prevalence of 1 in 75,000 to 1 in 200,000).

Ongoing Regulatory-Track Programs

• Vitiligo (CUV105): Phase III pivotal trial underway; results expected 2026
• Xeroderma pigmentosum (CUV156): Phase II
• Variegate porphyria: Early clinical development
• Acute ischemic stroke (CUV801): Phase IIa completed

8. Related Peptides

See also: PT-141 (Bremelanotide), Melanotan II, Setmelanotide (Imcivree), Alpha-MSH (Alpha-Melanocyte Stimulating Hormone), KPV (Alpha-MSH Fragment)

Afamelanotide belongs to the melanocortin peptide family and is structurally and pharmacologically related to several other compounds:

• Bremelanotide (PT-141, Vyleesi): A cyclic melanocortin receptor agonist derived from Melanotan II, approved by the FDA for hypoactive sexual desire disorder in premenopausal women. Acts primarily at MC3R and MC4R.
• Melanotan II: A synthetic cyclic analog of alpha-MSH with broader melanocortin receptor activity (MC1R-MC5R). Not approved for medical use; widely sold as a tanning peptide on the gray market.
• Setmelanotide (Imcivree): A selective MC4R agonist approved by the FDA for rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency). Structurally distinct from afamelanotide.
• Alpha-MSH: The endogenous 13-amino-acid melanocortin peptide from which afamelanotide is derived. Less potent and much shorter half-life than afamelanotide.
• KPV: A C-terminal tripeptide fragment of alpha-MSH with anti-inflammatory properties, primarily investigated for gut inflammation.

9. References

1. [1] Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. DOI PubMed
2. [2] Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of Dermatology. DOI PubMed
3. [3] Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddad L, et al. (2015). Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. DOI PubMed
4. [4] Fabrikant J, Touloei K, Engelman DE. (2013). A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of Drugs in Dermatology. PubMed
5. [5] Minder EI, Barman-Aksoezen J, Schoenfeld N. (2017). Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clinical Pharmacokinetics. DOI PubMed
6. [6] Brites A, Breusegem S, Gasser S. (2016). Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology. DOI PubMed
7. [7] McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH. (2018). Afamelanotide in the treatment of dermatologic disease. Skin Therapy Letter. PubMed
8. [8] Rodriguez GM, Diaz BL. (2021). Afamelanotide: An orphan drug with potential for broad dermatologic applications. Journal of Drugs in Dermatology. PubMed
9. [9] Haylett AK, Sherris D, Sherris J, Roby Y, et al. (2020). Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatology. PubMed
10. [10] Kaelin U, Aellig K, Baker T, et al. (2023). A feasibility and safety study of afamelanotide in acute stroke patients -- an open label, proof of concept, phase IIa clinical trial. BMC Neurology. DOI PubMed
11. [11] Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. (2005). Effect of [Nle4, D-Phe7]-alpha-MSH on melanin synthesis in humans with MC1R variant alleles. Peptides. PubMed
12. [12] Scenesse FDA Prescribing Information (2019). SCENESSE (afamelanotide) implant, for subcutaneous use: Full Prescribing Information. U.S. Food and Drug Administration. PubMed
13. [13] European Medicines Agency (2014). Scenesse: EPAR - Product Information. European Medicines Agency. PubMed
14. [14] Wensink D, Wagenmakers MAEM, Barman-Aksoezen J, Friesema ECH, Wilson JHP, van Rosmalen J, Langendonk JG. (2024). Afamelanotide for treatment of the protoporphyrias: impact on quality of life and laboratory parameters in a US cohort. Orphanet Journal of Rare Diseases. PubMed
15. [15] Schafer M, Stauber T, et al. (2025). German cohort observational study to investigate the short- and long-term safety and clinical effectiveness of afamelanotide 16 mg (SCENESSE) in patients with erythropoietic protoporphyria (EPP). Journal of the European Academy of Dermatology and Venereology. PubMed
16. [16] Wensink D, et al. (2021). Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Review of Clinical Pharmacology. DOI PubMed
17. [17] Clinuvel Pharmaceuticals (2023). Afamelanotide reduces DNA photodamage in xeroderma pigmentosum (CUV156). Clinuvel Technical Note / ClinicalTrials.gov. PubMed
18. [18] Wensink D, et al. (2023). Afamelanotide is associated with dose-dependent protective effect from liver damage related to erythropoietic protoporphyria. Life. DOI PubMed
19. [19] Wensink D, et al. (2023). Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. Therapeutic Advances in Rare Disease. PubMed
20. [20] Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. (2021). Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-alpha-MSH and setmelanotide. Cell Research. DOI PubMed